| Similar Articles |
|---|
 |
The Motley Fool
October 28, 2009
Brian Orelli |
Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably.   |
The Motley Fool
July 28, 2010
Brian Orelli |
Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense. |
The Motley Fool
April 24, 2008
Brian Orelli |
Illumina Ignites This biochip maker is on fire. |
The Motley Fool
July 24, 2008
Brian Orelli |
Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth. |
The Motley Fool
February 4, 2009
Brian Orelli |
43% Growth! Yee-Haw! Illumina rocks another quarter. |
The Motley Fool
October 24, 2007
Brian Orelli |
Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down. |
The Motley Fool
October 22, 2008
Jim Mueller |
Illuminating Illumina Did the DNA analysis equipment maker miss, meet, or beat expectations? Well, it's complicated. |
The Motley Fool
April 27, 2011
Brian Orelli |
Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby. |
The Motley Fool
February 6, 2009
Brian Orelli |
1,111 Reasons to Love This Company Intuitive Surgical's already installed base of 1,111 da Vinci surgical machines will drive sales through the use of consumables. |
The Motley Fool
February 8, 2010
Brian Orelli |
An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement. |
The Motley Fool
July 25, 2007
Brian Orelli |
Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row. |
The Motley Fool
January 14, 2010
Brian Orelli |
$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome. |
The Motley Fool
February 6, 2008
Brian Orelli |
Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward? |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out. |
The Motley Fool
October 25, 2007
Brian Orelli |
Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter. |
The Motley Fool
July 22, 2011 |
Green Mountain Coffee Roasters Earnings Preview Investors are on the edge of their seats, hoping that Green Mountain Coffee Roasters will top analyst expectations for the fourth consecutive quarter. on Wednesday, July 27. |
Chemistry World
January 8, 2013
Andrew Turley |
Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities. |
The Motley Fool
February 13, 2009
Brian Orelli |
Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered. |
The Motley Fool
August 25, 2009
Brian Orelli |
That's How You Want to Spend Investors' Money? A high-growth buyback? Really? On the surface, the buyback of Illumina shares looks like a pretty poor use of capital, but in truth, the move might not be that bad for investors. |
The Motley Fool
October 24, 2008
Brian Orelli |
Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell. |
The Motley Fool
April 22, 2009
Brian Orelli |
Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away. |
The Motley Fool
April 27, 2007
Brian Orelli |
Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note. |
Chemistry World
January 27, 2012
Sarah Houlton |
Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach. |
The Motley Fool
July 26, 2007
Brian Orelli |
Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit. |
The Motley Fool
April 25, 2008
Brian Orelli |
Affymetrix Learns About Inertia Slower sales of its older chips drag down growth. |
Chemistry World
November 21, 2013
Phillip Broadwith |
Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests. |
The Motley Fool
October 24, 2007 |
Illumina Shines: Fool by Numbers The genetic research tech provider released third-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
August 12, 2009
Brian Orelli |
The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing. |
The Motley Fool
August 7, 2006
Stephen D. Simpson |
Affymetrix: Price Always Matters Affymetrix has legit technology, but that doesn't mean it has infinite value for investors. |
Chemistry World
May 29, 2014
Hepeng Jia |
Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market. |
The Motley Fool
June 14, 2010
Bruce Bigelow |
Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval. |
The Motley Fool
May 26, 2011
Andrew Tonner |
Does Agilent Technologies Deserve a Spot in Your Portfolio? Let's take a look at Agilent Technologies and some of its closest peers. |
IEEE Spectrum
February 2010
Mark Anderson |
Genome as Commodity In a few years, millions will have purchased their own genome. The cultural ramifications of a $100 genome are as wide and deep as those of any other recent innovation, including search engines and cellphones. |
Bio-IT World
February 2007
Robert M. Frederickson |
Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform. |
Bio-IT World
February 2006
Kevin Davies |
Solexa Readies 1G Genetic Analyzer Solexa, one of the firms vying to crack the $1,000 genome threshold, has officially launched its first commercial genome sequencing instrument. |
The Motley Fool
July 12, 2011
Brian Orelli |
Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test. |
The Motley Fool
January 3, 2012
Alex Planes |
Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on. |
The Motley Fool
January 11, 2008
Brian Orelli |
Biochip Packaging: Some Settling May Occur Biochip maker Illumina settles its disputes about patents with Affymetrix. |
The Motley Fool
May 13, 2011
Karl Thiel |
Pacific Biosciences Has a PR Problem PacBio is hard to break down to a sound bite, but that could spell opportunity for long-term investors. |
The Motley Fool
August 19, 2011
Alexander Crawford |
DNA Sequencing: The Next High-Growth Market in Biotech? We compiled a list of companies with a hand in the DNA sequencing market. Should you add these companies to your watch list? |
Bio-IT World
June 2006 |
News Blast Spectral Spend... Nanoscale News... Testmakers... |
